CAD 0.89
(-4.3%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | -100.0% |
2020 | 1.09 Million CAD | 0.0% |
2019 | - CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | - CAD | 0.0% |
2024 Q1 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q2 | 2.07 Million CAD | 2.39% |
2023 Q1 | 2.02 Million CAD | 0.0% |
2023 Q3 | - CAD | -100.0% |
2023 Q4 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Appili Therapeutics Inc. | 8.18 Million CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | 13.78 Million CAD | 100.0% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 6.64 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Oncolytics Biotech Inc. | 423 Thousand CAD | 100.0% |
Sernova Corp. | 136.12 Thousand CAD | 100.0% |